2001 Market Street
Suite 3915 Unit #15
Philadelphia, PA 19103
United States
(267) 225-7416
https://www.contexttherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Martin A. Lehr | Co-Founder, President, CEO & Director | 725.25k | N/A | 1984 |
Ms. Jennifer Minai-Azary | CFO & Treasurer | 533.65k | N/A | 1978 |
Mr. Alex C. Levit Esq. | Chief Legal Officer & Corporate Secretary | 512.1k | N/A | 1979 |
Mr. Christopher Beck M.B.A. | Senior Vice President of Operations | N/A | N/A | N/A |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.